|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Goat / IgG|
|Immunogen||Synthetic peptide sequence (GAKKDTKDSRPK) corresponding to the internal amino acids of AGR2|
|Purification||Antigen affinity chromatography|
|Storage buffer||TBS, pH 7.3, with 0.5% BSA|
|Contains||0.02% sodium azide|
|Storage Conditions||-20° C, Avoid Freeze/Thaw Cycles|
|Tested Applications||Dilution *|
|Immunocytochemistry (ICC)||2 µg/ml|
|Immunofluorescence (IF)||2 µg/ml|
|Immunohistochemistry (IHC)||Assay Dependent|
|Western Blot (WB)||0.1-0.3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
This antibody is predicted to react with canine and mouse based on sequence homology.
AGR2 (anterior gradient protein 2) and AGR3 are members of the anterior gradient homolog family. They are secreted cytoplasmic proteins which are involved in metastasis induction and p53 tumour supressor inhibition. They may serve as molecular markers and potential therapeutic targets for hormone-responsive breast tumours. AGR2 is ubiquitously expressed with upregulated expression in prostate cancer, breast cancer, lung cancer, renal carcinomas and endometrial carcinomas. AGR2 expression is positively correlated with that of the estrogen receptor (ER) and is negatively correlated with that of the epidermal growth factor receptor (EGFR).
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.